Which class of drugs does nirogacestat belong to?

Nirogacestat (nirogacestat) is a gamma secretase inhibitor and a targeted therapy drug mainly used to treat progressive desmoid tumors (PDT). Desmoid tumors are rare, benign tumors that usually occur in the abdomen, intestines, or other tissues. Although this tumor is not classified as cancer, its rapid proliferation can cause local compression symptoms and affect the patient's organ function and quality of life. Therefore, nirogalastat, as a targeted drug, can effectively control the disease and reduce symptoms.

γ-Secretase plays an important role within cells, especially during tumor cell proliferation and spread. In the pathogenesis of desmoid tumors, γ-secretase activity is considered to be one of the key factors. By inhibiting the activity of this enzyme, Nirogastat can effectively slow down the proliferation of tumor cells and prevent continued tumor growth. This mechanism of action gives nirogalastat unique advantages in the treatment of desmoid tumors.

As aγ-secretase inhibitor, nilogacestat has high targeting and low systemic toxicity, which allows it to reduce damage to normal cells and reduce the occurrence of side effects compared with traditional chemotherapy drugs during treatment. The primary clinical indication for nirogalastat is progressive desmoid tumors, particularly in adult patients requiring systemic therapy. The drug is administered orally, is easy for patients to use, and can improve patients' quality of life to a certain extent.

In short, Nilogacestat is an innovative targeted therapy drug that effectively controls the progression of desmoid tumors, delays tumor growth, and improves patient symptoms by targeting the activity of γ-secretase. This type of drug belongs to targeted therapy drugs and has broad prospects in the field of targeted cancer treatment.

Reference materials:https://www.drugs.com/mtm/nirogacestat.html